Work

Mycoplasma pneumoniae infection outbreak in Guangzhou, China after COVID-19 pandemic

Year: 2024

Type: article

Abstract: Mycoplasma pneumoniae ( M. pneumoniae ) is a common pathogen causing respiratory diseases in children. This study aimed to characterize epidemiological and disease severity shifts of M. pneumoniae : infections in Guangzhou, China during and after the coronavirus disease 2019 (COVID-19) pandemic. Throat swab samples were obtained from 5405 hospitalized patients with symptoms of acute respiratory infections to detect M. pneumoniae . Differences in epidemiological and clinical characteristics of M. pneumoniae : infections were investigated during 2020–2022 and after COVID-19 pandemic (2023). M. pneumoniae were detected in 849 (15.6%, 849/5405) patients. The highest annual positive rate was 29.4% (754/2570) in 2023, followed by 5.3% (72/1367) in 2022, 1.2% (12/1015) in 2021, and 2.0% (11/553) in 2020, with significantly increasing annual prevalence from 2020 to 2023. M. pneumoniae incidence peaked between July and December post-COVID-19 pandemic in 2023, with the highest monthly positive rate (56.4%, 165/293). Clinical characteristics and outcomes of patients with M. pneumoniae did not vary between periods during and after COVID-19 pandemic except that patients with M. pneumoniae post-COVID-19 pandemic were more likely to develop fever. Patients with severe M. pneumoniae pneumonia (SMPP) were more likely to develop respiratory complications, myocardial damage, and gastrointestinal dysfunction than those with non-SMPP. Patients with SMPP had lower lymphocytes, CD3 + T cells, CD4 + T cells, CD8 + T cells, B cells, and higher IL-4, IL-6, IL-10 levels than those with non-SMPP. Bronchoalveolar lavage fluid specimens from infected patients were obtained to identify macrolide resistance mutations. Macrolide-resistant M. pneumoniae (MRMP) proportion in 2023 was 91.1% (215/236). Outbreaks of M. pneumoniae : occurred in Guangzhou, China in 2023 upon Non-pharmaceutical interventions easing. Despite the increasing incidence of M. pneumoniae , the disease severity remained similar during and after the COVID-19 pandemic.

Source: Virology Journal

DOI: 10.1186/s12985-024-02458-z